321 related articles for article (PubMed ID: 16228969)
21. [The causes and mechanism of selective motor neuron death in amyotrophic lateral sclerosis].
Van den Bosch L
Verh K Acad Geneeskd Belg; 2006; 68(4):249-69. PubMed ID: 17214440
[TBL] [Abstract][Full Text] [Related]
22. Advanced EMG techniques in diagnostics of spinal muscular atrophies and motor neuron disease--magnetic stimulation, single fiber EMG and macro EMG.
Bartousek J; Hlustík P; Grenarová O; Beranová M
Acta Univ Palacki Olomuc Fac Med; 1993; 136():37-9. PubMed ID: 7887198
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases.
Alisky JM; Davidson BL
Hum Gene Ther; 2000 Nov; 11(17):2315-29. PubMed ID: 11096437
[TBL] [Abstract][Full Text] [Related]
24. Targeted stem cell transplantation strategies in ALS.
Lepore AC; Maragakis NJ
Neurochem Int; 2007 Jun; 50(7-8):966-75. PubMed ID: 17055612
[TBL] [Abstract][Full Text] [Related]
25. [Gene Therapies in Motor Neuron Diseases ALS and SMA].
Günther R
Fortschr Neurol Psychiatr; 2023 Apr; 91(4):153-163. PubMed ID: 36822211
[TBL] [Abstract][Full Text] [Related]
26. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
27. Human-induced pluripotent stem cells pave the road for a better understanding of motor neuron disease.
Winner B; Marchetto MC; Winkler J; Gage FH
Hum Mol Genet; 2014 Sep; 23(R1):R27-34. PubMed ID: 24821704
[TBL] [Abstract][Full Text] [Related]
28. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.
Mitsumoto H; Ulug AM; Pullman SL; Gooch CL; Chan S; Tang MX; Mao X; Hays AP; Floyd AG; Battista V; Montes J; Hayes S; Dashnaw S; Kaufmann P; Gordon PH; Hirsch J; Levin B; Rowland LP; Shungu DC
Neurology; 2007 Apr; 68(17):1402-10. PubMed ID: 17452585
[TBL] [Abstract][Full Text] [Related]
29. Lack of caspase-dependent apoptosis in spinal motor neurons of the wobbler mouse.
Bigini P; Atzori C; Fumagalli E; Cagnotto A; Barbera S; Migheli A; Mennini T
Neurosci Lett; 2007 Oct; 426(2):106-10. PubMed ID: 17890007
[TBL] [Abstract][Full Text] [Related]
30. Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases.
Finiels F; Gimenez y Ribotta M; Barkats M; Samolyk ML; Robert JJ; Privat A; Revah F; Mallet J
Neuroreport; 1995 Dec; 7(1):373-8. PubMed ID: 8742491
[TBL] [Abstract][Full Text] [Related]
31. Motor neuron syndromes in cancer patients.
Forsyth PA; Dalmau J; Graus F; Cwik V; Rosenblum MK; Posner JB
Ann Neurol; 1997 Jun; 41(6):722-30. PubMed ID: 9189033
[TBL] [Abstract][Full Text] [Related]
32. [Animal models of amyotrophic lateral sclerosis].
Yamanaka K
Rinsho Shinkeigaku; 2007 Nov; 47(11):934-7. PubMed ID: 18210840
[TBL] [Abstract][Full Text] [Related]
33. [Motor neuron diseases].
Petri S; Meyer T
Nervenarzt; 2011 Jun; 82(6):697-706. PubMed ID: 21626001
[TBL] [Abstract][Full Text] [Related]
34. Does VEGF represent a potential treatment for amyotrophic lateral sclerosis?
Iłzecka J
Curr Opin Investig Drugs; 2006 Jan; 7(1):54-9. PubMed ID: 16425672
[TBL] [Abstract][Full Text] [Related]
35. Cellular therapies in motor neuron diseases.
Nayak MS; Kim YS; Goldman M; Keirstead HS; Kerr DA
Biochim Biophys Acta; 2006; 1762(11-12):1128-38. PubMed ID: 16872810
[TBL] [Abstract][Full Text] [Related]
36. [Pathogenesis and therapeutic perspectives for amyotrophic lateral sclerosis (ALS)].
Abe K
Rinsho Shinkeigaku; 2007 Nov; 47(11):790-4. PubMed ID: 18210800
[TBL] [Abstract][Full Text] [Related]
37. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model.
Ishigaki A; Aoki M; Nagai M; Warita H; Kato S; Kato M; Nakamura T; Funakoshi H; Itoyama Y
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1037-44. PubMed ID: 17984685
[TBL] [Abstract][Full Text] [Related]
38. Gene therapy for neurodegenerative diseases based on lentiviral vectors.
Nanou A; Azzouz M
Prog Brain Res; 2009; 175():187-200. PubMed ID: 19660657
[TBL] [Abstract][Full Text] [Related]
39. Genetic disorders of motor neurons.
Cole N; Siddique T
Semin Neurol; 1999; 19(4):407-18. PubMed ID: 10716663
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies.
Bruijn LI; Cudkowicz M
Expert Rev Neurother; 2006 Mar; 6(3):417-28. PubMed ID: 16533145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
